
CATX
Healthcare · Medical Devices · $113.9M market cap
$0.9431+0.10 (+12.0%)Nov 13, 4:22 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +16.5% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 15, 2027 · upcoming | After the close | -0.26 | — | — |
| Nov 9, 2026 | After the close | -0.24 | -0.27 | -12.5% |
| Aug 10, 2026 | After the close | -0.27 | -0.22 | +18.5% |
| May 11, 2026 | After the close | -0.32 | -0.25 | +21.9% |
| Mar 26, 2026 | Time not confirmed | -0.35 | -0.51 | -43.0% |
| Nov 10, 2025 | After the close | -0.32 | -0.35 | -9.4% |
| Aug 13, 2025 | Before the open | -0.29 | -0.30 | -3.4% |
| May 12, 2025 | After the close | -0.27 | -0.25 | +7.4% |
| Mar 26, 2025 | Time not confirmed | -0.27 | -0.57 | -114.3% |
| Nov 12, 2024 | After the close | -0.20 | -0.21 | -5.0% |
| Aug 12, 2024 | After the close | -0.16 | -0.18 | -12.5% |
| May 15, 2024 | Before the open | -0.28 | -0.20 | +28.6% |
| Mar 31, 2024 | After the close | -0.04 |
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not…
| -0.09 |
| -125.0% |
| Nov 14, 2023 | After the close | -0.40 | -0.40 | 0.0% |
| Aug 11, 2023 | Before the open | -0.30 | -0.40 | -33.3% |
| May 15, 2023 | After the close | -0.01 | -0.01 | 0.0% |
| Feb 16, 2023 | After the close | -0.01 | -0.02 | -100.0% |
| Nov 14, 2022 | After the close | -0.01 | -0.03 | -200.0% |
| Sep 28, 2022 | After the close | -0.01 | -0.01 | 0.0% |
| May 10, 2022 | After the close | -0.10 | -0.10 | 0.0% |
| Feb 8, 2022 | After the close | -0.10 | -0.10 | 0.0% |
| Nov 10, 2021 | After the close | -0.10 | -0.20 | -100.0% |
| Sep 21, 2021 | After the close | -0.01 | -0.01 | 0.0% |
| May 13, 2021 | After the close | -0.10 | -0.10 | 0.0% |
| Feb 9, 2021 | After the close | -0.10 | -0.10 | 0.0% |
| Nov 10, 2020 | After the close | -0.20 | -0.10 | +50.0% |
| Sep 17, 2020 | After the close | -0.01 | -0.02 | -100.0% |
| May 12, 2020 | After the close | -0.15 | -0.10 | +33.3% |
| Feb 11, 2020 | After the close | -0.20 | -0.10 | +50.0% |
| Nov 12, 2019 | After the close | -0.20 | -0.13 | +35.0% |
| Sep 24, 2019 | After the close | -0.02 | -0.02 | 0.0% |
| May 9, 2019 | After the close | -0.20 | -0.20 | 0.0% |
| Feb 12, 2019 | After the close | -0.20 | -0.20 | 0.0% |
| Nov 8, 2018 | After the close | -0.20 | -0.20 | 0.0% |
| Sep 25, 2018 | After the close | -0.03 | -0.04 | -33.3% |
| May 3, 2018 | After the close | -0.30 | -0.20 | +33.3% |
| Feb 8, 2018 | After the close | -0.20 | -0.30 | -50.0% |